Tempus, a Chicago-based biotech firm launched by businessman Eric Lefkofsky, has made large strides during the COVID-19 pandemic. Initially, the company focused on assisting physicians in tackling cancer by empowering them to analyze patient genomic data. Recently, though, Lefkofsky and Tempus have been touting the massive dataset the company has acquired. The granular genomic data acquired by Tempus is particularly useful for pharmaceutical companies developing new drugs. It also makes ample use of artificial intelligence to analyze clinical data and produce useful results for both physicians and researchers. According to Eric Lefkofsky, Tempus has data about roughly a third of cancer patients in the United States. The company has recently raised $200 million in capital to finance its planned business expansions.
Eric wants Tempus to apply its cutting-edge precision healthcare technology and expansive data infrastructure to tackle problems like infectious diseases, mental illness, and heart disease. This is a huge step forward for the rapidly-growing company. 2020 has been its profitable year yet. In November, Tempus publicly announced partnerships with medical multinational J&J and the American Society of Clinical Oncology to expand and share the company’s datasets. “The goal is to create ‘smart’ laboratory tests by including and analyzing other types of data along with the test result, and by making the tests as personalized as possible,” Jensen explained. The COVID-19 pandemic has given Tempus the opportunity to both expand the scope of its operations and assist in taking on the global pandemic.
Be the first to reply